Puma Biotechnology Inc (PBYI) : Wednesdays money flow data in Puma Biotechnology Inc (PBYI) suggests that the bulls made the most of the weakness in the stock. The inflow of money into the stock on upticks was $0.98 million, whereas, $0.69 million worth of transactions were done on downticks. The ratio between the two, uptick and downtick stood at 1.42, in favor of the bulls. The total money flow into the stock was $0.29 million clearly indicating that the smart money has been buying into the stock on weakness.
In comparison, the money flow in block deals was $0 million. The total value of block trades done on upticks was $0 million. Puma Biotechnology Inc (PBYI) fell $0.16 and traded at $70.25, down -0.22% for the day, over previous days close. On a weekly basis, the shares are 3.19% over the previous weeks close.
Puma Biotechnology, Inc. has dropped 1.04% in the last five trading days, however, the shares have posted positive gains of 13.77% in the last 4 weeks. Puma Biotechnology, Inc. is up 121.91% in the last 3-month period. Year-to-Date the stock performance stands at -14.21%.
Puma Biotechnology Inc (PBYI) : 5 analysts are covering Puma Biotechnology Inc (PBYI) and their average rating on the stock is 1.8, which is read as a Buy. 3 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 2, which recommends a Buy affirms that they expect a large upside in the stock from the current levels. A total of 2 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.
Puma Biotechnology Inc (NYSE:PBYI): stock was range-bound between the intraday low of $66.27 and the intraday high of $71.65 after having opened at $70.85 on Wednesdays session. The stock finally closed in the red at $70.85, a loss of -4.47%. The stock remained in the red for the whole trading day. The total traded volume was 1,219,132 shares. The stock failed to cross $71.65 in Wednesdays trading. The stocks closing price on Thursday was $70.41.
Puma Biotechnology, Inc. is a biopharmaceutical company that focuses on the acquisition, development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seeks to further develop those drug candidates for commercial use. It licenses the rights to three drug candidates. It is developing PB272 (neratinib (oral)) for the treatment of patients with human epidermal growth factor receptor type 2 (HER2), positive breast cancer, and patients with non-small cell lung cancer, breast cancer and other solid tumors that have a HER2 mutation. It is developing PB272 (neratinib (intravenous)) for the treatment of patients with advanced cancer. PB357 is an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4.